Pragma Pharmaceuticals announced the relaunch of Moxatag (amoxicillin extended-release) tablets. Pragma acquired Moxatag from Shionogi in March 2014.

Moxatag is the only once-daily amoxicillin formulation available. It is currently approved for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes. Amoxicillin exerts its bactericidal action against susceptible organisms during the stage of multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide.

RELATED: Antibiotic Formulations

Moxatag is available in 775mg tablets in 30-count bottles.

For more information call (414) 434-6604 or visit